Literature DB >> 33433886

A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.

Giuseppe Pelosi1,2, Fabrizio Bianchi3, Elisa Dama3, Jasna Metovic4, Marco Barella5, Angelica Sonzogni6, Adriana Albini7, Mauro Papotti4, Yulan Gong8, Namrata Vijayvergia9.   

Abstract

In the gastro-entero-pancreatic (GEP) tract, neuroendocrine neoplasms (NENs) include well differentiated neuroendocrine tumors (NETs) and high-grade NE carcinomas (NECs), which are thought to make up separate and mutually exclusive tumor entities. Little is known, however, as to whether there may be any pathogenetic link between them. Clustering analysis of a 10-gene panel generated from a previously reported next-generation sequencing analysis on 48 GEP-NENs with clinical annotations was used in the study. Unsupervised cluster analysis showed three histology-independent clusters, namely, C1, C2, and C3, which accounted for 44% of patients but the entire array of mutations. All but two NECs fell into the clusters, yet with different prevalence rates (p < 0.0001). A model was devised according to which NETs were likely to evolve into NECs upon progression of C3 into C1 and C2, despite different morphology. The median Ki-67 labeling index was 5% in C3 showing better prognosis and 50% in C1 and C2 experiencing worse prognosis, with an impressive intra-tumor heterogeneity of diversely proliferating tumor areas. This study suggests that a subset of large cell NECs in the gastroenteropancreatic tract may evolve from pre-existing well-differentiated NETs.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Carcinoma; Cluster analysis; Gastro-entero-pancreatic tract; Mutation; NEC; NET; Neuroendocrine; Pathogenesis; Prognosis; Transition; Tumor

Mesh:

Year:  2021        PMID: 33433886     DOI: 10.1007/s12022-020-09659-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  5 in total

1.  The Next Steps for Endocrine Pathology.

Authors:  Sylvia L Asa; Lori A Erickson; Ozgur Mete
Journal:  Endocr Pathol       Date:  2022-02-28       Impact factor: 3.943

Review 2.  Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.

Authors:  Stefano La Rosa
Journal:  Endocr Pathol       Date:  2021-03-31       Impact factor: 3.943

Review 3.  Management of Large Cell Neuroendocrine Carcinoma.

Authors:  Virginia Corbett; Susanne Arnold; Lowell Anthony; Aman Chauhan
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244

4.  An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.

Authors:  Atsuko Kasajima; Björn Konukiewitz; Anna Melissa Schlitter; Wilko Weichert; Günter Klöppel
Journal:  Virchows Arch       Date:  2021-09-09       Impact factor: 4.064

5.  A real-life treatment cohort of pancreatic neuroendocrine tumors: High-grade increase in metastases confers poor survival.

Authors:  Wu-Hu Zhang; He-Li Gao; Wen-Sheng Liu; Yi Qin; Zeng Ye; Xin Lou; Fei Wang; Yue Zhang; Xue-Min Chen; Jie Chen; Xian-Jun Yu; Qi-Feng Zhuo; Xiao-Wu Xu; Shun-Rong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-10       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.